105 related articles for article (PubMed ID: 10767352)
21. A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice.
Arab A; Behravan J; Razazan A; Gholizadeh Z; Nikpoor AR; Barati N; Mosaffa F; Badiee A; Jaafari MR
J Drug Target; 2018 Apr; 26(4):365-372. PubMed ID: 28972792
[TBL] [Abstract][Full Text] [Related]
22. Her-2/ neu altered peptide ligand-induced CTL responses: implications for peptides with increased HLA affinity and T-cell-receptor interaction.
Dionne SO; Myers CE; Smith MH; Lake DF
Cancer Immunol Immunother; 2004 Apr; 53(4):307-14. PubMed ID: 14605764
[TBL] [Abstract][Full Text] [Related]
23. Cross-reactive cytotoxic T lymphocytes against human immunodeficiency virus type 1 protease and gamma interferon-inducible protein 30.
Mason RD; Bowmer MI; Howley CM; Grant MD
J Virol; 2005 May; 79(9):5529-36. PubMed ID: 15827167
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxic Activity and Memory T Cell Subset Distribution of
Kuznetsova M; Lopatnikova J; Shevchenko J; Silkov A; Maksyutov A; Sennikov S
Front Immunol; 2019; 10():1017. PubMed ID: 31143180
[TBL] [Abstract][Full Text] [Related]
25. Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer.
Goedegebuure PS; Douville CC; Doherty JM; Linehan DC; Lee KY; Ganguly EK; Eberlein TJ
Cell Immunol; 1997 Feb; 175(2):150-6. PubMed ID: 9023420
[TBL] [Abstract][Full Text] [Related]
26. Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals.
Anderson BW; Peoples GE; Murray JL; Gillogly MA; Gershenson DM; Ioannides CG
Clin Cancer Res; 2000 Nov; 6(11):4192-200. PubMed ID: 11106231
[TBL] [Abstract][Full Text] [Related]
27. Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients.
Woll MM; Fisher CM; Ryan GB; Gurney JM; Storrer CE; Ioannides CG; Shriver CD; Moul JW; McLeod DG; Ponniah S; Peoples GE
J Clin Immunol; 2004 Jul; 24(4):449-61. PubMed ID: 15163902
[TBL] [Abstract][Full Text] [Related]
28. The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells.
zum Büschenfelde CM; Metzger J; Hermann C; Nicklisch N; Peschel C; Bernhard H
J Immunol; 2001 Aug; 167(3):1712-9. PubMed ID: 11466395
[TBL] [Abstract][Full Text] [Related]
29. An in vitro-transcribed-mRNA polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and Influenza for use as a functional control in human immune monitoring studies.
Nielsen JS; Wick DA; Tran E; Nelson BH; Webb JR
J Immunol Methods; 2010 Aug; 360(1-2):149-56. PubMed ID: 20637775
[TBL] [Abstract][Full Text] [Related]
30. Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.
Gall VA; Philips AV; Qiao N; Clise-Dwyer K; Perakis AA; Zhang M; Clifton GT; Sukhumalchandra P; Ma Q; Reddy SM; Yu D; Molldrem JJ; Peoples GE; Alatrash G; Mittendorf EA
Cancer Res; 2017 Oct; 77(19):5374-5383. PubMed ID: 28819024
[TBL] [Abstract][Full Text] [Related]
31. Tumor antigen-specific T cells for immune monitoring of dendritic cell-treated glioblastoma patients.
Müller I; Altherr D; Eyrich M; Flesch B; Friedmann KS; Ketter R; Oertel J; Schwarz EC; Technau A; Urbschat S; Eichler H
Cytotherapy; 2016 Sep; 18(9):1146-61. PubMed ID: 27424145
[TBL] [Abstract][Full Text] [Related]
32. Generation of tumor-reactive CTL against the tumor-associated antigen HER2 using retrovirally transduced dendritic cells derived from CD34+ hemopoietic progenitor cells.
Meyer zum Büschenfelde C; Nicklisch N; Rose-John S; Peschel C; Bernhard H
J Immunol; 2000 Oct; 165(7):4133-40. PubMed ID: 11034426
[TBL] [Abstract][Full Text] [Related]
33. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
[TBL] [Abstract][Full Text] [Related]
34. IL-15 induces strong but short-lived tumor-infiltrating CD8 T cell responses through the regulation of Tim-3 in breast cancer.
Heon EK; Wulan H; Macdonald LP; Malek AO; Braunstein GH; Eaves CG; Schattner MD; Allen PM; Alexander MO; Hawkins CA; McGovern DW; Freeman RL; Amir EP; Huse JD; Zaltzman JS; Kauff NP; Meyers PG; Gleason MH; Overholtzer MG; Wiseman SS; Streutker CD; Asa SW; McAlindon TP; Newcomb PO; Sorensen PM; Press OA
Biochem Biophys Res Commun; 2015 Aug; 464(1):360-6. PubMed ID: 26141233
[TBL] [Abstract][Full Text] [Related]
35. Distinct patient responses to activation of T-cells by free HER-2, G89 (777-789) and protected LRMK-linked HER-2, {AE-39 [p776 (Ava-774-788)], AE-47 [(Ava-776-788)] and AE-37[p776 (774-788)]} peptides could lead to development of personalized cancer vaccines.
Li Y; Matsueda S; Efferson CL; Tsuda N; Kawano K; Gao H; Peoples GE; Ioannides CG
Anticancer Res; 2009 Jan; 29(1):41-58. PubMed ID: 19331132
[TBL] [Abstract][Full Text] [Related]
36. Presence of Autoreactive, MHC Class I-Restricted, Calcium-Sensing Receptor (CaSR)-Specific CD8+ T Cells in Idiopathic Hypoparathyroidism.
Mahtab S; Vaish U; Saha S; Singh A; Goswami R; Rani R
J Clin Endocrinol Metab; 2017 Jan; 102(1):167-175. PubMed ID: 27805845
[TBL] [Abstract][Full Text] [Related]
37. Patients with inflammatory bowel disease (IBD) reveal increased induction capacity of intracellular interferon-gamma (IFN-gamma) in peripheral CD8+ lymphocytes co-cultured with intestinal epithelial cells.
Bisping G; Lügering N; Lütke-Brintrup S; Pauels HG; Schürmann G; Domschke W; Kucharzik T
Clin Exp Immunol; 2001 Jan; 123(1):15-22. PubMed ID: 11167992
[TBL] [Abstract][Full Text] [Related]
38. Ovarian and breast cytotoxic T lymphocytes can recognize peptides from the amino enhancer of split protein of the Notch complex.
Babcock B; Anderson BW; Papayannopoulos I; Castilleja A; Murray JL; Stifani S; Kudelka AP; Wharton JT; Ioannides CG
Mol Immunol; 1998 Dec; 35(17):1121-33. PubMed ID: 10395201
[TBL] [Abstract][Full Text] [Related]
39. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain.
Okano F; Storkus WJ; Chambers WH; Pollack IF; Okada H
Clin Cancer Res; 2002 Sep; 8(9):2851-5. PubMed ID: 12231526
[TBL] [Abstract][Full Text] [Related]
40. Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine.
Hueman MT; Stojadinovic A; Storrer CE; Dehqanzada ZA; Gurney JM; Shriver CD; Ponniah S; Peoples GE
Cancer Immunol Immunother; 2007 Feb; 56(2):135-46. PubMed ID: 16783576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
